Navigation Links
Sofie Biosciences Launches a High Performance, Benchtop Preclinical PET System Using New Generation Detector Technology
Date:4/4/2011

CULVER CITY, Calif., April 4, 2011 /PRNewswire/ -- Sofie Biosciences, a developer of molecular imaging systems and agents, announced the launch of GENISYS4, their new benchtop small animal PET system. Introduced today at the 2011 American Association for Cancer Research Annual Meeting, this compact, preclinical multimodality PET system provides researchers with the ability to non-invasively visualize and measure the biology of disease and therapeutic response over the course of a study.

(Logo: http://photos.prnewswire.com/prnh/20101208/LA13841LOGO)

As molecular imaging becomes an essential tool for translational research, Sofie believes it is time for PET technology to be more widely accessible, cost-effective, and convenient for integration into a variety of labs.

To achieve this, PET must reduce its size and complexity while increasing usability and performance.  Furthermore, the valuable animal models at the heart of the study should have their physiology carefully maintained over the course of the experiment. GENISYS4 is the answer, utilizing new advances in detector architecture to offer unmatched sensitivity, and novel Docking Station and Imaging Chamber designs to provide safe conditions in an intuitive workflow experience. Compared to the traditional small animal PET systems that are three times the cost and ten times the size, GENISYS4 doesn't require specially trained personnel or expensive site planning to have researchers up and running with minimal cost and effort.

"GENISYS4 is launching an era of compact molecular imaging systems, just as PC companies have created a new world away from mainframes. At only 18 inches wide and 24 inches tall, GENISYS4 is the smallest PET imaging system in the industry, yet the most sensitive," said Patrick Phelps, Sofie Biosciences' President and Chief Executive Officer. "We are very excited to be the first to introdu
'/>"/>

SOURCE Sofie Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sofie Biosciences Raises $2M to Support Development of Diagnostic Imaging Agents and Devices
2. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
3. Neurocrine Biosciences to Present at the 10th Annual Needham Healthcare Conference
4. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
5. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
6. Neurocrine Biosciences to Present at the Roth 23rd Annual OC Growth Stock Conference
7. Sangamo BioSciences Announces Presentation at the Cowen and Company 31st Annual Health Care Conference
8. Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections
9. Neurocrine Biosciences to Present at Citis 2011 Global Health Care Conference
10. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
11. Avantra Biosciences and MedTrust Online Partner to Develop Clinically Important Protein Biomarker Assays for Improving Cancer Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com ... available in its catalogue: The Market ... http://www.reportlinker.com/p02051938/The-Market-for-Medical-Devices-in-EMEA .html The European, Middle Eastern and ... medical devices. As part of its coverage, this ... concentrates on the EMEA medical device markets and ...
(Date:8/20/2014)... Aug. 20, 2014  Quantum Materials Corporation (OTCQB:QTMM) ... of patent families from Bayer Technology Services GmbH, the ... Bayer AG of Leverkusen, Germany ... broad intellectual property protection for advances Quantum ... dot (QD) manufacturing. In addition, the Bayer patents ...
(Date:8/19/2014)... , Aug. 19, 2014 Talyst, a market ... exhibiting at the 2014 NPPA Summer Conference in ... be showcasing its 340B software products and services.   ... splitting solutions, supplying over 400 customers with a variety ... 340B solutions including its latest solution, AutoSplit® Contract Pharmacy ...
Breaking Medicine Technology:The Market for Medical Devices in EMEA 2The Market for Medical Devices in EMEA 3The Market for Medical Devices in EMEA 4The Market for Medical Devices in EMEA 5Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 2Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 3Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 4Talyst Exhibits at the NPPA Summer Conference 2
... at American Society of Clinical Oncology 2009 Annual Meeting ... , , SAN FRANCISCO, June 2 Medivation, ... presentation of new clinical results from a Phase 1-2 ... castration-resistant prostate cancer (CRPC) patients. The new findings, ...
... , Panel Discussant Focuses on Longer Duration of Remission ... Complete Remissions Achieved with Standard Chemotherapy , , ... MTA: CTIC) announced today that at the poster and ... Section at the 2009 American Society of Clinical Oncology ...
Cached Medicine Technology:Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients 2Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients 3Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients 4Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients 5Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 2Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 3Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 4Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 5Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 6
(Date:8/20/2014)... News) -- Pigs, hearts transplanted into baboons survived for ... as previously achieved, researchers report. The work is ... organs to shorten transplant waiting lists. In this ... baboons, abdomens. The genetic engineering and new methods of ... the hearts to survive for more than a year. ...
(Date:8/20/2014)... Reinberg HealthDay Reporter WEDNESDAY, ... cancer cells grow may help doctors diagnose and treat the ... investigators have found that the deadliest skin cancers occur most ... a long history of sun exposure. These lesions also ... Rapid cell growth -- called "high mitotic rate" -- ...
(Date:8/20/2014)... persistent and deadliest infectious diseases in the world, killing ... who study tuberculosis have long debated its origins. New ... Africa to seals and sea lions that brought the ... people there before Europeans landed on the continent. , ... Source of New World Human Tuberculosis," was published in ...
(Date:8/20/2014)... New York, New York (PRWEB) August 20, 2014 ... associated with the use of power morcellators ( http://www.injurybeacon.com/power-morcellator/ ... Liebhard LLP notes that two U.S. Senators from New ... (FDA) to seek a recall of the devices. In ... Charles Schumer, both Democrats, also implored the agency to ...
(Date:8/20/2014)... contrast to evidence that the amygdala stimulates stress ... Research Center, Emory University have found that the ... during the early development of nonhuman primates. , ... Journal of Neuroscience . , The amygdala is ... important for responses to threatening situations and learning ...
Breaking Medicine News(10 mins):Health News:Pigs' Hearts Beat for a Year in Baboons' Abdomens 2Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 2Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 3Health News:New research shows seals and sea lions likely spread tuberculosis to humans 2Health News:New research shows seals and sea lions likely spread tuberculosis to humans 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 4Health News:Maturing brain flips function of amygdala in regulating stress hormones 2Health News:Maturing brain flips function of amygdala in regulating stress hormones 3
... Red Compounds Financial Problems, According ... July 14 HealthLeaders-InterStudy, a,leading provider of healthcare ... the hospitals in the Los Angeles market are ... doing relatively well financially,and those that are barely ...
... and Blue Shield companies to,promote workplace wellness programs ... Recognizing that chronic,illness accounts for 75 percent ... on" approach to improving employee health and wellness ... prevention,and management. At a press briefing this morning ...
... of Health,and Hospitals announced its intent to award HMS ... and cost avoidance services,to the state,s Medicaid program. This ... the highest score in a competitive procurement process,for the ... the state, HMS recovered more than,$36 million for the ...
... Zimmer Holdings, Inc.,(NYSE: ZMH ; SWX: ZMH) statement:, ... that Zimmer,s,NexGen(R) knee implant had been recalled. In fact, ... used for minimally invasive,surgeries (MIS) and not the implant ... to a single surgical instrument and that additional,instrumentation options ...
... Bring Better Quality of Care and Improved Business Performance ... ... PITTSBURGH, July 14 Vocollect Healthcare Systems, Inc.,and SouthMed, Inc., ... healthcare market, announce a,strategic partnership, whereby SouthMed will resell AccuNurse,voice-assisted care ...
... Optimism is good for heart health, at least among ... Medical Center researcher Robert Gramling, M.D., D.Sc., found that ... cardiovascular disease actually experienced a three times lower incidence ... data did not support the same conclusion among women. ...
Cached Medicine News:Health News:Fragmented Los Angeles Hospital Market Provides Health Systems with Little Leverage to Negotiate Higher Reimbursement 2Health News:Employers Take Active Role in Promoting Workplace Wellness 2Health News:Employers Take Active Role in Promoting Workplace Wellness 3Health News:Louisiana Department of Health and Hospitals Announces Intent to Award Cost Containment Services Contract to HMS 2Health News:Zimmer Holdings Issues Clarification Regarding NexGen Knee System 2Health News:Zimmer Holdings Issues Clarification Regarding NexGen Knee System 3Health News:SouthMed, Inc. and Vocollect Healthcare Systems Announce Reseller Agreement 2Health News:Positive thinking is prescription for the heart 2
An enzyme-linked immuno-sorbent assay for the detectionand quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Jerome Halo Traction Units provide optimum immobilization for unstable injuries of the spine. The Generation 80 superstructure is available with either 2-point (serrated disk), or 3-point (flexion/ex...
... Boston Scoliosis Brace™ for neuromuscular ... a lightweight, soft, and easy ... maximum comfort. The Soft ... of non-cracking orthopedic grade copolymer ...
An indirect immunofluorescence antibody test for the qualitative and semi-quantitative detection of endomysial antibodies (EMA) in human serum as an aid in the diagnosis of celiac disease and dermati...
Medicine Products: